Clinical Trial of 13-Valent Pneumococcal Conjugate Vaccine

Inclusion Criteria:

1. Healthy infants or children who are aged 2 months (at least 6 weeks), 7-11 months, 12-23 months and 2-5 years (before the 6th birthday);

2. Participants' guardians provide legal identity document and participants'vaccination record;

3. Participants' guardians understand and voluntarily sign the informed consent form;

4. Participants' guardians can follow all study procedures and stay in contact duringthe study.

Exclusion Criteria:

1. Received any pneumococcal vaccine prior to enrollment;

2. History of bacterial pneumonia or invasive pneumococcal diseases (IPDs) caused byStreptococcus pneumoniae, as confirmed by laboratory tests;

3. History of allergy or adverse reactions to the vaccine or vaccine components, orhistory of allergy, such as urticaria, dyspnea, angioedema and abdominal pain;

4. History of dystocia, asphyxia rescue and nervous system damage at birth for infantsunder 2 years of age;

5. Congenital malformations or developmental disorders, genetic defects, severemalnutrition, history of asthma;

6. Autoimmune diseases (such as systemic lupus erythematosus), immunodeficiencydiseases or immunosuppressive diseases (such as AIDS, organ transplantation);

7. Severe cardiovascular diseases, diabetes, liver diseases, kidney diseases, malignanttumours.

8. Have/have suffered from a serious neurological disorder (epilepsy or convulsions) ormental illness or have a family history of such diseases.

9. History of thyroidectomy, asplenia, functional asplenia; asplenia or splenectomycaused by any reasons;

10. Diagnosed abnormal blood coagulation function (eg, lack of blood coagulationfactors, blood coagulopathy, abnormal platelets level), history of obvious bleeding,hematoma or bruising after intramuscular injection or venipuncture.

11. Consecutively received ≥14 days of corticosteroid, any other immunosuppressivetherapy (excluding corticosteroid spray therapy for allergic rhinitis and surfacecorticosteroid therapy for acute non-concurrent dermatitis), or cytotoxic therapyprior to enrollment for infants aged 6 weeks to 2 months or within 6 months prior toenrollment for children aged 7 months to 5 years.

12. Received blood products prior to enrollment for children aged 2 months or within 3months prior to enrollment for children aged 7 months to 5 years. Receipt ofHepatitis B immunoglobulin one month prior to enrollment is an exception.

13. Received other investigational drugs within 60 days prior to enrollment, or plan toreceive such drugs during the study;

14. Received live attenuated vaccine within 14 days prior to enrollment;

15. Received subunit or inactivated or other vaccine within 7 days prior to enrollment;

16. Acute diseases or acute onset of chronic diseases within 7 days prior to enrollment;

17. Had fever (axillary temperature≥ 37.3 Degree Celsius) before vaccination;

18. In the investigator's judgment, the participant has any other factors that make himor her unfit to participate in the clinical trial.